{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:29:20Z","timestamp":1789223360414,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases. Incorporating an oxazolidinone on the scaffold mitigated toxicological issues often seen with topoisomerase inhibitors. Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class. Preclinical evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine <jats:italic>Staphylococcus aureus<\/jats:italic> infection model that served as a surrogate for predicting efficacious exposures for the treatment of <jats:italic>Neisseria gonorrhoeae<\/jats:italic> infections. A wide safety margin to the efficacious exposure in toxicological evaluations supported progression to Phase 1. Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.<\/jats:p>","DOI":"10.1038\/srep11827","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T11:14:55Z","timestamp":1436872495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases"],"prefix":"10.1038","volume":"5","author":[{"given":"Gregory S.","family":"Basarab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther H.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Barvian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Doig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Galullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudhan","family":"Gowravaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kimzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Morningstar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kutschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita D.","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manos","family":"Perros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virna J. A.","family":"Schuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Walkup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"BFsrep11827_CR1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/cid\/cit614","volume":"58","author":"KA Rodvolk","year":"2014","unstructured":"Rodvolk, K. A. & McConeghy, K. W. Methicillin-resistant Staphylococcus aureus therapy: past, present and future. Clin. Infect. Dis. 58, S20\u2013S27 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep11827_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1586\/14787210.2014.906902","volume":"12","author":"M Unemo","year":"2014","unstructured":"Unemo, M., Golparian, D. & Shafer, W. M. Challenges with gonorrhea in the era of multi-drug and extensively drug resistance \u2013 are we on the right track? Expert Rev. Anti Infect. Ther. 12, 653\u2013656 (2014).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"BFsrep11827_CR3","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397\u20132405 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep11827_CR4","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1021\/ja808014h","volume":"131","author":"JC Ruble","year":"2009","unstructured":"Ruble, J. C. et al. Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates. J. Am. Chem. Soc. 131, 3991\u20133997 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep11827_CR5","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1021\/jm501174m","volume":"57","author":"GS Basarab","year":"2014","unstructured":"Basarab, G. S. et al. Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold \u2013 SAR and in vivo characterization. J. Med. Chem. 57, 9078\u20139095 (2014).","journal-title":"J. Med. Chem."},{"key":"BFsrep11827_CR6","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1021\/ol503256h","volume":"16","author":"GS Basarab","year":"2014","unstructured":"Basarab, G. S. et al. Synthesis of a tetrahydronaphthyridine spiropyrimidinetrione DNA gyrase inhibiting antibacterial agent - differential substitution at all five carbon atoms of pyridine. Org. Lett. 16, 6456\u20136459 (2014).","journal-title":"Org. Lett."},{"key":"BFsrep11827_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.04124-14","volume":"59","author":"MD Huband","year":"2015","unstructured":"Huband, M. D. et al. In vitro antibacterial activity of AZD0914: a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative and atypical bacteria. Antimicrob. Agents and Chemother. 59, 467\u2013474 (2015).","journal-title":"Antimicrob. Agents and Chemother."},{"key":"BFsrep11827_CR8","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1128\/AAC.03090-14","volume":"58","author":"S Jacobsson","year":"2014","unstructured":"Jacobsson, S. et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob. Agents Chemother. 58, 5585\u20135588 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/AAC.04456-14","volume":"59","author":"RA Alm","year":"2015","unstructured":"Alm, R. A. et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 59, 1478\u20131486 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/clpt.2014.106","volume":"96","author":"B Spellberg","year":"2014","unstructured":"Spellberg, B. & Shlaes, D. Prioritized current unmet needs for antibacterial therapies. Clin. Pharmacol. Ther. 96, 151\u2013153 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFsrep11827_CR11","unstructured":"CDC Fact Sheet, Gonorrhea Treatment Guidelines. (2013) Available at: http:\/\/www.cdc.gov\/nchhstp\/newsroom\/docs\/Gonorrhea-Treatment-Guidelines-FactSheet.pdf. (Accessed: 28 April 2015)."},{"key":"BFsrep11827_CR12","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1111\/j.1749-6632.2011.06215.x","volume":"1230","author":"M Unemo","year":"2011","unstructured":"Unemo, M. & Shafer, W. M. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230, E19\u2013E28 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFsrep11827_CR13","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/jac\/dku118","volume":"69","author":"T Morita-Ishihara","year":"2014","unstructured":"Morita-Ishihara, T. et al. Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. J. Antimicrob. Chemother. 69, 2086\u20132090 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep11827_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1099\/jmm.0.007641-0","volume":"58","author":"J Tapsall","year":"2009","unstructured":"Tapsall, J. et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58, 683\u2013687 (2009).","journal-title":"J. Med. Microbiol."},{"key":"BFsrep11827_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJMp1112456","volume":"366","author":"GA Bolan","year":"2012","unstructured":"Bolan, G. A., Sparling, P. F. & Wasserheit, J. N. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 366, 485\u2013487 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep11827_CR16","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1128\/AAC.45.10.2755-2764.2001","volume":"45","author":"D Ince","year":"2001","unstructured":"Ince, D. & Hooper, D. C. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents and Chemother. 45, 2755\u20132764 (2001).","journal-title":"Antimicrob. Agents and Chemother."},{"key":"BFsrep11827_CR17","doi-asserted-by":"publisher","first-page":"iv5","DOI":"10.1136\/sextrans-2013-051162","volume":"89","author":"RD Kirkcaldy","year":"2013","unstructured":"Kirkcaldy, R. D., Kidd, S., Weinstock, H. S., Papp, J. R. & Bolan, G. A. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006\u2013June 2012. Sexually Transmitted Infections 89, iv5\u2013iv10 (2013).","journal-title":"Sexually Transmitted Infections"},{"key":"BFsrep11827_CR18","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1128\/AAC.00496-08","volume":"52","author":"MT Black","year":"2008","unstructured":"Black, M. T. et al. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother. 52, 3339\u20133349 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR19","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1128\/JCM.00656-14","volume":"52","author":"JE Ross","year":"2014","unstructured":"Ross, J. E., Scangarella-Oman, N. E., Flamm, R. K. & Jones, R. N. Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J. Clin. Microbiol. 52, 2629\u20132632 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep11827_CR20","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1021\/jm300690s","volume":"55","author":"F Reck","year":"2012","unstructured":"Reck, F. et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile. J. Med. Chem. 55, 6916\u20136933 (2012).","journal-title":"J. Med. Chem."},{"key":"BFsrep11827_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/id500013t","volume":"1","author":"GS Bisacchi","year":"2015","unstructured":"Bisacchi, G. S. & Manchester, J. I. A new-class antibacterial\u2014almost. Lessons in drug discovery and development: a critical analysis of &gt;50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect. Dis. 1, 4\u201341 (2015).","journal-title":"ACS Infect. Dis."},{"key":"BFsrep11827_CR22","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1021\/cr4003984","volume":"114","author":"C Mayer","year":"2014","unstructured":"Mayer, C. & Janin, Y. L. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem. Rev. 114, 2313\u20132342 (2014).","journal-title":"Chem. Rev."},{"key":"BFsrep11827_CR23","unstructured":"Federal Register, Determination That ALBAMYCIN (Novobiocin Sodium) Capsule, 250 Milligrams, Was Withdrawn From Sale for Reasons of Safety or Effectiveness. (2011) Available at: https:\/\/www.federalregister.gov\/articles\/2011\/01\/19\/2011-1000\/determination-that-albamycin-novobiocin-sodium-capsule-250-milligrams-was-withdrawn-from-sale-for. (Accessed: 28 April 2015)."},{"key":"BFsrep11827_CR24","unstructured":"Barvian, K., Basarab, G. S., Gowravaram, M. R., Hauck, S. I. & Zhou, F. Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections. USP 8, 658, 641 (2014)."},{"key":"BFsrep11827_CR25","unstructured":"Basarab, G. S., Gowravaram, M. R., Hauck, S. I. & Zhou, F. Compounds and methods for treating bacterial infections. United States Patent 8, 889, 671 (2014)."},{"key":"BFsrep11827_CR26","unstructured":"European Medicines Agency, Pre-authorisation Evaluation of Medicines for Human Use. (2009), Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/2010\/01\/WC500060988.pdf. (Accessed: 28 April 2015)."},{"key":"BFsrep11827_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1517\/14740338.3.5.405","volume":"3","author":"PJ Harwood","year":"2002","unstructured":"Harwood, P. J. & Giannoudis, P. V. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms Expert Opinion in Drug Safety 3, 405\u2013414 (2002).","journal-title":"Expert Opinion in Drug Safety"},{"key":"BFsrep11827_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1039\/c3tx50028d","volume":"2","author":"AT Doherty","year":"2013","unstructured":"Doherty, A. T. et al. Bone marrow micronucleus frequencies in the rat after oral administration of cyclophosphamide, hexamethylphosphoramide or gemifloxacin for 2 and 28 days Toxicol. Res. 2, 321\u2013327 (2013).","journal-title":"Toxicol. Res."},{"key":"BFsrep11827_CR29","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1021\/jm901241e","volume":"52","author":"F Lovering","year":"2009","unstructured":"Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752\u20136756 (2009).","journal-title":"J. Med. Chem."},{"key":"BFsrep11827_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1086\/338403","volume":"34","author":"K Attassi","year":"2002","unstructured":"Attassi, K., Hershberger, E., Alam, R. & Zervos, M. J. Thrombocytopenia associated with linezolid therapy Clin. Infect. Dis. 34, 695\u2013698 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep11827_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1445-5994.2009.01996.x","volume":"39","author":"CY Cheah","year":"2009","unstructured":"Cheah, C. Y., De Keulenaer, B. & Leahy, M. F. Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern. Med. J. 39, 619\u2013623 (2009).","journal-title":"Intern. Med. J."},{"key":"BFsrep11827_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1574886308666140106154754","volume":"9","author":"J Sousa","year":"2014","unstructured":"Sousa, J., Alves, G., Fortuna, A. & Falcao, A. Third and fourth generation fluoroquinolone antibacterials: A systematic review of safety and toxicity profiles. Curr. Drug Safety 9, 89\u2013105 (2014).","journal-title":"Curr. Drug Safety"},{"key":"BFsrep11827_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas, M. E., Rafailidis, P. I. & Rosmarakis, E. S. Arrhythmias associated with fluoroquinolone therapy. Int. J. Antimicrob. Agents 29, 374\u2013379 (2007).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFsrep11827_CR34","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1111\/j.1540-8159.2003.00367.x","volume":"26","author":"D Katritsis","year":"2003","unstructured":"Katritsis, D. & Camm, A. J. Quinolones: Cardioprotective or cardiotoxic? PACE 26, 2317\u20132320 (2003).","journal-title":"PACE"},{"key":"BFsrep11827_CR35","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"KJ Aldred","year":"2014","unstructured":"Aldred, K. J., Kerns, R. J. & Osheroff, N. Mechanism of quinolone action and resistance. Biochemistry 53, 1565\u20131574 (2014).","journal-title":"Biochemistry"},{"key":"BFsrep11827_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","volume":"70","author":"JJ Champoux","year":"2001","unstructured":"Champoux, J. J. DNA topisomerases: structure, function and mechanism. Annu. Rev. Biochem. 70, 369\u2013413 (2001).","journal-title":"Annu. Rev. Biochem."},{"key":"BFsrep11827_CR37","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1093\/nar\/gkt124","volume":"41","author":"KJ Aldred","year":"2013","unstructured":"Aldred, K. J., McPherson, S. A., Turnbough, C. L., Kerns, R. J. & Osheroff, N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 41, 4628\u20134639 (2013).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep11827_CR38","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1093\/nar\/gkn539","volume":"36","author":"XS Pan","year":"2008","unstructured":"Pan, X. S., Dias, M., Palumbo, M. & Fisher, L. M. Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. Nucleic Acids Res. 36, 5516\u20135529 (2008).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep11827_CR39","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1021\/cb500629k","volume":"9","author":"K Drlica","year":"2014","unstructured":"Drlica, K. et al. Bypassing fluoroquinolone resistance with quinazolinediones: Studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem. Biol. 9, 2895\u20132904 (2014).","journal-title":"ACS Chem. Biol."},{"key":"BFsrep11827_CR40","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1128\/AAC.00247-08","volume":"52","author":"AA Miller","year":"2008","unstructured":"Miller, A. A. et al. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob. Agents Chemother. 52, 2806\u20132812 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR41","doi-asserted-by":"publisher","first-page":"8712","DOI":"10.1021\/jm401208b","volume":"56","author":"GS Basarab","year":"2013","unstructured":"Basarab, G. S. et al. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J. Med. Chem. 56, 8712\u20138735 (2013).","journal-title":"J. Med. Chem."},{"key":"BFsrep11827_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/jac\/48.4.545","volume":"48","author":"J Ruiz","year":"2001","unstructured":"Ruiz, J. et al. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J. Antimicrob. Chemother. 48, 545\u2013548 (2001).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep11827_CR43","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1128\/AAC.35.8.1647","volume":"35","author":"H Yoshida","year":"1991","unstructured":"Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. & Nakamura, S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35, 1647\u20131650 (1991).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR44","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1124\/dmd.104.000349","volume":"32","author":"SK Balani","year":"2004","unstructured":"Balani, S. K. et al. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab. Dispos. 32, 1092\u20131095 (2004).","journal-title":"Drug Metab. Dispos."},{"key":"BFsrep11827_CR45","unstructured":"Craig, W. A. & Dalhoff, A. in Handbook of experimental pharmacology (eds Kuhlman, J., Dalhoff, A. & Zeiller, H. J ) 208\u2013232 (Springer-Verlag, Berlin, Germany, 1998)."},{"key":"BFsrep11827_CR46","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1128\/AAC.46.6.1665-1670.2002","volume":"46","author":"D Andes","year":"2002","unstructured":"Andes, D. & Craig, W. A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46, 1665\u20131670 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2011.00107","volume":"2","author":"AE Jerse","year":"2011","unstructured":"Jerse, A. E. et al. Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front. Microbiol. 2, 1\u201313 (2011).","journal-title":"Front. Microbiol."},{"key":"BFsrep11827_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig, W. A. Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1\u201310 (1998).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep11827_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","volume":"159","author":"JE Leggett","year":"1989","unstructured":"Leggett, J. E. et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159, 281\u2013292 (1989).","journal-title":"J. Infect. Dis."},{"key":"BFsrep11827_CR50","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest, A. et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073\u20131081 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR51","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1128\/AAC.37.9.2007","volume":"37","author":"KM Kam","year":"1997","unstructured":"Kam, K. M., Lo, K. K., Lai, C., Lee, Y. S. & Chan, C. B. Ofloxacin susceptibilities of 5,667 Neisseria gonorrhoeae strains isolated in Hong Kong. Antimicrob. Agents Chemother. 37, 2007\u20132008 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003495-200059010-00002","volume":"59","author":"DJ Diekema","year":"2000","unstructured":"Diekema, D. J. & Jones, R. N. Oxazolidinones Drugs 59, 7\u201316 (2000).","journal-title":"Drugs"},{"key":"BFsrep11827_CR53","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.mcna.2006.07.007","volume":"90","author":"BA Cunha","year":"2006","unstructured":"Cunha, B. A. Antimicrobial therapy of multidrug-resistant S. pneumoniae, vancomycin-resistant Enterococci and methicillin-resistant S. aureus. Med. Clin. N. Am. 90, 1165\u20131182 (2006).","journal-title":"Med. Clin. N. Am."},{"key":"BFsrep11827_CR54","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","volume":"46","author":"D Andes","year":"2002","unstructured":"Andes, D., van Ogtrop, M. L., Peng, J. & Craig, W. A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46, 3484\u20133489 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","volume":"22","author":"WA Craig","year":"1995","unstructured":"Craig, W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22, 89\u201396 (1995).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFsrep11827_CR56","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","volume":"11","author":"F Van Bambeke","year":"2005","unstructured":"Van Bambeke, F., Michot, J.-M., Van Eldere, J. & Tulkens, P. M. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11, 256\u2013280 (2005).","journal-title":"Clin. Microbiol. Infect."},{"key":"BFsrep11827_CR57","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","volume":"42","author":"CR Rayner","year":"2003","unstructured":"Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C. & Schentag, J. J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42, 1411\u20131423 (2003).","journal-title":"Clin. Pharmacokinet."},{"key":"BFsrep11827_CR58","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","volume":"63","author":"KF Croom","year":"2003","unstructured":"Croom, K. F. & Goa, K. L. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63, 2769\u20132802 (2003).","journal-title":"Drugs"},{"key":"BFsrep11827_CR59","unstructured":"B. Braun Medical Inc., Ceftriaxone for Injection and Dextrose Injection (2012) Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050796orig1s011lbledt.pdf. (Accessed: 8th March 2015)."},{"key":"BFsrep11827_CR60","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3109\/00498258709167406","volume":"17","author":"AC Popick","year":"1987","unstructured":"Popick, A. C. et al. Plasma protein binding of ceftriaxone. Xenobiotica. 17, 1139\u20131145 (1987).","journal-title":"Xenobiotica."},{"key":"BFsrep11827_CR61","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bcp.2012.07.007","volume":"84","author":"AB Shapiro","year":"2012","unstructured":"Shapiro, A. B. & Andrews, B. Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors. Biochem. Pharmacol. 84, 900\u2013904 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"BFsrep11827_CR62","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1128\/AAC.00226-09","volume":"53","author":"BLM de Jonge","year":"2009","unstructured":"de Jonge, B. L. M., Kutschke, A., Uria-Nickelsen, M., Kamp, H. D. & Mills, S. D. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob. Agents Chemother. 53, 3331\u20133336 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR63","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1128\/AAC.31.7.1054","volume":"31","author":"J Blaser","year":"1987","unstructured":"Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentrations to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31, 1054\u20131060 (1987).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep11827_CR64","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1086\/518003","volume":"195","author":"VH Tam","year":"2007","unstructured":"Tam, V. H. et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone. J. Infect. Dis. 195, 1818\u20131827 (2007).","journal-title":"J. Infect. Dis."},{"key":"BFsrep11827_CR65","unstructured":"ClinicalTrials.gov, A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914. (2014) Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01929629?term=AZD0914&rank=2. (Accessed: 8th March 2015)."}],"updated-by":[{"DOI":"10.1038\/srep14157","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep11827","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep11827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep11827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T14:06:34Z","timestamp":1672927594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep11827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,18]]}},"alternative-id":["BFsrep11827"],"URL":"https:\/\/doi.org\/10.1038\/srep11827","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]},"assertion":[{"value":"23 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2015","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are or have been employed by AstraZeneca and declare no competing financial interests otherwise.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11827"}}